LACTIN-V
| Clinical data | |
|---|---|
| Other names | CTV-05; CTV05; Lactobacillus crispatus CTV-05 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem SID | |
| DrugBank | |
| UNII | |
LACTIN-V, also known as CTV-05 or as Lactobacillus crispatus CTV-05, is a live biopharmaceutical medication containing a strain of Lactobacillus crispatus (L. crispatus) which is under development for the treatment of urinary tract infections (UTIs) and bacterial vaginosis (BV).[1][2] It is administered intravaginally and is described as the first vaginal microbiome (VMB)-based live biotherapeutic product (LBP).[2]
Depletion of hydrogen peroxide (H2O2)-producing Lactobacillus strains such as Lactobacillus crispatus in the vagina has been strongly associated with BV and UTIs.[2] Most commercially available probiotic Lactobacillus strains are not vaginal strains and do not appear to improve vaginal or urinary health outcomes.[2] The Centers for Disease Control and Prevention (CDC)'s Sexually Transmitted Infections Treatment Guidelines (2021) noted that intravaginal LACTIN-V produced a considerably lower recurrence of BV following initial antibiotic treatment with metronidazole in a randomized controlled trial.[3][4] However, the guidelines also noted that LACTIN-V is not yet Food and Drug Administration (FDA)-approved or commercially available.[3]
As of December 2021, LACTIN-V is in phase 2/3 clinical trials for the treatment of UTIs and is in phase 2 trials for the treatment of BV.[1] It was originated by GyneLogix and is under development by Osel Inc., the National Institute of Allergy and Infectious Diseases, and other organizations.[1]
See also
[edit]References
[edit]- ^ a b c "CTV 05". Adis Insight.
- ^ a b c d Lagenaur LA, Hemmerling A, Chiu C, Miller S, Lee PP, Cohen CR, Parks TP (June 2021). "Connecting the Dots: Translating the Vaginal Microbiome Into a Drug". J Infect Dis. 223 (12 Suppl 2): S296–S306. doi:10.1093/infdis/jiaa676. PMC 8502429. PMID 33330916.
- ^ a b "Bacterial Vaginosis - STI Treatment Guidelines". www.cdc.gov. July 19, 2021.
- ^ Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A (May 2020). "Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis". N Engl J Med. 382 (20): 1906–1915. doi:10.1056/NEJMoa1915254. PMC 7362958. PMID 32402161.
External links
[edit]- CTV-05 (LACTIN-V; Lactobacillus crispatus CTV-05) - AdisInsight
- CTV-05 (LACTIN-V, Lactobacillus crispatus CTV-05, CTV 05) - Synapse
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |